CTLA4 and glioblastoma: SubMap analysis demonstrated that compared with Cluster 2 GBM patients, Cluster 1 patients in both the TCGA and CGGA cohorts were more sensitive to CTLA4 and PD1 inhibitors (Figures 3B,D).